More News

Centessa Pharmaceuticals to be acquired by Lilly

Jim Cornall -
Nxera Pharma Co., Ltd.’s partner, Centessa Pharmaceuticals Limited, has entered into a definitive agreement regarding its acquisition by Eli...

Smart drugs to fight cancer

Jim Cornall -
How cancer cells can be targeted without damaging healthy tissue is one of the major challenges facing oncology today....

OpenProtein.AI expands partnership with Boehringer Ingelheim on AI-driven antibody discovery

Jim Cornall -
OpenProtein.AI has announced an expansion of its partnership with Boehringer Ingelheim to co-develop specialised antibody discovery and optimisation workflows....

New biomarker helps assess aggression of glioblastoma

Jim Cornall -
Researchers from the Biomedical Data Science Laboratory (BDSLab) at the ITACA Institute of the Universitat Politècnica de València in...

Protein helps cancer cells survive treatment

Jim Cornall -
Researchers at Umeå University in Sweden have contributed new insights into how cancer cells protect themselves from cell death....

Base to Base biotech podcast 53: Diagnosing autism and improving transplant outcomes

Jim Cornall -
On this week’s episode, as April 2 is World Autism Day, we have a conversation with Manish Arora, CEO...

IND approval for bispecific ADC

Jim Cornall -
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced that the Investigational New Drug (IND) application for SKB103, its self-developed novel...

World’s largest clinically linked spatial biology atlas launched

Jim Cornall -
Bioptimus has announced the launch of its Spatial Tissue Embedding Learning Atlas (STELA), a multinational spatial data generation initiative...

Changing the search for rare disease diagnoses with AI breakthrough

Jim Cornall -
A newly developed AI tool can speed up the search for the genetic causes of rare diseases, a process...

Precision medicine helps more patients receive genetic diagnosis

Jim Cornall -
A collaboration between Karolinska Institutet, Karolinska University Hospital, and SciLifeLab has integrated whole genome sequencing into routine diagnostic investigations...

Tumour DNA in blood after pre-surgery treatments predicts if breast cancer will return

Jim Cornall -
Fragments of tumour DNA in the bloodstream of patients with breast cancer can predict whether they are likely to...

Radiotherapy may help reduce risk of lymphoedema in patients with breast cancer

Jim Cornall -
Patients with breast cancer may be able to avoid lymphoedema, which can occur after surgery to remove lymph nodes...

UCB picks Rowen as $2bn manufacturing campus

Jim Cornall -
The State of Georgia, Gwinnett County and the Rowen Foundation have announced that global biopharmaceutical company UCB has selected...

Researchers move closer to preventing pandemics

admin -
Researchers have developed an AI tool that can help determine whether unfamiliar bacteria carry genetic features linked to disease....

Copper overload kills cancer cells

Jim Cornall -
Cuproptosis was discovered in 2022. It was a previously unknown type of cell death caused by an excess of...

Lyme disease vaccine shows strong efficacy in phase 3 trial

Jim Cornall -
Pfizer Inc. and Valneva SE have announced topline results from the phase 3 VALOR (Vaccine Against Lyme for Outdoor...

FDA approves pill for plaque psoriasis

Jim Cornall -
Johnson & Johnson has announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE (icotrokinra), an...

Crossbow Therapeutics raises $77m to treat cancer

Jim Cornall -
Crossbow Therapeutics, Inc. has raised $77m in a Series B financing that will support the completion of the CROSSCHECK-001...

Base to Base biotech podcast 52: Ketamine for depression, and a new company in the kidney disease space

Jim Cornall -
On this week’s episode, we chat with Hans Eriksson, chief medical officer (CMO) of HMNC Brain Health, about ketamine...

Excalipoint Therapeutics launches with $68.7m to develop T-Cell engager therapies

Jim Cornall -
Excalipoint Therapeutics has announced an oversubscribed $68.7m seed financing round to support advancement of its proprietary technology platforms and...

FDA clearance for refractory gout treatment

Jim Cornall -
Innorna has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application...